Overactive bladder - pharmacological treatment

Sacomani, Carlos Alberto Ricetto; Almeida, Fernando G.; Silvinato, Antônio; Bernardo, Wanderley Marques

doi:10.1590/1806-9282.65.4.487

Cited by 3 publications

(3 citation statements)

References 52 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Side effects of imipramine can limit the use of this drug, especially the possibility of arrhythmias. It should not be prescribed to patients with psychiatric disorders, patients who use monoaminoxidase inhibitors, or those at an increased risk of arrhythmias [ 54 ].…”

Section: Treatmentsmentioning

confidence: 99%

Management of mixed urinary incontinence: IUGA committee opinion

Jha,

Jeppson,

Dokmeci

et al. 2024

Int Urogynecol J

View full text Add to dashboard Cite

Introduction and hypothesis Mixed urinary incontinence (MUI) is defined by the International Urogynecology Association (IUGA) and International Continence Society as the complaint of involuntary leakage of urine associated with urgency and also with exertion, effort, sneezing or coughing. It therefore implies the coexistence of both stress urinary incontinence (SUI) and urgency urinary incontinence (UUI). MUI is a heterogeneous diagnosis that requires an assessment of its individual components of SUI and UUI. Management requires an individualised approach to the symptom components. The aim of this review is to identify the assessment/investigations and management options for MUI. Methods A working subcommittee from the IUGA Research & Development (R&D) Committee was created and volunteers invited from the IUGA membership. A literature review was performed to provide guidance focused on the recommended assessment and management of MUI. The document was then evaluated by the entire IUGA R&D Committee and IUGA Board of Directors and revisions made. The final document represents the IUGA R&D Committee Opinion. Results The R&D Committee MUI opinion paper provides guidance on the assessment and management of women with MUI and summarises the evidence-based recommendations. Conclusions Mixed urinary incontinence is a complex problem and successful management requires alleviation of both the stress and urge components. Care should be individualised based on patient preferences. Further research is needed to guide patients in setting goals and to determine which component of MUI to treat first. The evidence for many of the surgical/procedural treatment options for MUI are limited and needs to be explored in more detail.

show abstract

Section: Treatmentsmentioning

confidence: 99%

Management of mixed urinary incontinence: IUGA committee opinion

Jha,

Jeppson,

Dokmeci

et al. 2024

Int Urogynecol J

View full text Add to dashboard Cite

show abstract

“…It exerts a complex pharmacological impact through its antimuscarinic activity as well as serotonin and noradrenaline reuptake blocking properties. Imipramine has an indirect α-adrenergic effect, thus promoting detrusor relaxation and causing an increase in the intraurethral pressure [37].…”

Section: Antidepressantsmentioning

confidence: 99%

The Urogynecology Section of the Polish Society of Gynecologists and Obstetricians guidelines on the management of non-neurogenic overactive bladder syndrome in women

Grzybowska¹,

Rechberger²,

Wróbel³

et al. 2021

Ginekol Pol

View full text Add to dashboard Cite

show abstract

“…Mirabegron, a β3 adrenergic receptor agonist, is recommended as an alternative treatment for SRSs with muscarine antagonist monotherapy ( Sacomani et al, 2019 ). It significantly benefits the treatment of ureteral SRSs when compared to placebo or blank control ( Li et al, 2022 ; Van Besien et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Mirabegron and antimuscarinics for treating ureteral stent-related symptoms: a systematic review and meta-analysis of RCTs

Lu,

Li,

Zou

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: We conducted a meta-analysis to assess the efficacy and safety of mirabegron (50 mg/day) and antimuscarinics in treating ureteral stent-related symptoms (SRSs).Methods: All randomized controlled trials (RCTs) were identified by searching PubMed, Embase, Web of Science, and Cochrane Library. The RevMan version 5.3.0 software was used for statistical analysis.Results: This meta-analysis included five RCTs involving 317 patients. A fixed effects model revealed that mirabegron was superior to antimuscarinics in treating urinary symptoms (MD −1.39, 95% CI −2.63 to −0.15, p = 0.03) and general health (MD −1.65, 95% CI −2.60 to −0.69, p = 0.0007) 1 week after treatment initiation. We observed no significant differences in body pain (MD 0.05, 95% CI −1.06 to 1.15, p = 0.94), work performance (MD −0.86, 95% CI −1.77 to 0.06, p = 0.07), and sexual matters (MD 0.03, 95% CI −0.77 to 0.83, p = 0.94). Two weeks after treatment initiation, the ureteral stent symptom questionnaire (USSQ) revealed no significant differences between the two groups. The mirabegron group demonstrated a significant improvement in the quality of life (QoL) (MD −0.18, 95% CI −0.34 to −0.01, p = 0.03), while the International Prostate Symptom Score did not reveal a significant difference between the two groups (MD −0.74, 95% CI −1.79 to 0.32, p = 0.17). Regarding safety, a pooled data analysis presented that the incidence of constipation was lower in the mirabegron group (OR 0.10, 95% CI 0.01 to 0.77, p = 0.03). The mirabegron and antimuscarinics groups did not differ significantly concerning the risk of dry mouth (OR 0.15, 95% CI 0.02 to 1.27, p = 0.08).Conclusion: Mirabegron is superior to antimuscarinics in alleviating ureteral SRSs and improving QoL. Additionally, mirabegron 50 mg/day presented safety with a lower incidence of constipation.

show abstract

Overactive bladder - pharmacological treatment

Cited by 3 publications

References 52 publications

Management of mixed urinary incontinence: IUGA committee opinion

Management of mixed urinary incontinence: IUGA committee opinion

The Urogynecology Section of the Polish Society of Gynecologists and Obstetricians guidelines on the management of non-neurogenic overactive bladder syndrome in women

Mirabegron and antimuscarinics for treating ureteral stent-related symptoms: a systematic review and meta-analysis of RCTs

Contact Info

Product

Resources

About